Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (799)	5/3/2001 3:50:15 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 834

The Argatroban stroke trial (180 pts, 30 sites, P2, topline expected 2H02) are prompted by these and the company's own confirming preclinical work: Keio J Med 2000 Feb;49 Suppl 1:A141-4 Related Articles, Books The regional cerebral blood flow amelioration of argatroban in the acute stage of cerebral thrombosis. Yamashita T, Hayashida O, Nagamitsu T, Nagatsuna T, Wakuta Y, Fudaba H. Department of Neurosurgery, Central Hospital of Yamaguchi, Yamaguchi University, Japan. Cerebral blood flow changes by argatroban in the acute stage of cerebral thrombosis have been investigated with the use of stable xenon computed tomography (Xe/CT). The study group consisted of 14 cases (7 males, 7 females) with the average age of 59 years old (ranging from 21 to 79 years of age). We evaluated the cerebral blood flow change after an intravenous drip infusion of 10 mg of argatroban. After the administration of argatroban, we recognized a significant increase in the blood flow (24.4 +/- 5.0 ml/100 g/min to 28.4 +/- 2.7 ml/100 g/min, p < 0.05) in the blood flow area of lower than 30 ml/100 g/min in the affected vascular territory. As a conclusion, we found that argatroban improves ischemic symptoms through the amelioration of blood flow in the penumbra area. Publication Types: Clinical trial Controlled clinical trial Keio J Med 2000 Feb;49 Suppl 1:A138-40 Related Articles, Books A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction. Maruki Y, Onoda A, Matsuzaki M, Narabayashi Y, Sawada M, Shimazu K. Dept. of Neurology, Saitama Neuropsychiatric Institute, Yono, Japan. Argatroban, one of the arginine derivatives, has been reported to have a safe and potent antithrombin action. This compound is active in several animal models of thrombosis and also has been shown to improve general neurological symptomatology, general subjective symptomatology and general daily behavior in the patients with acute thrombosis. This was considered to reflect remarkable improvement of microcirculation. No published clinical data, however, exist on the effect of argatroban on cerebral blood flow (CBF) change during acute stroke. Three patients with acute cerebral infarction were subjected to this study. Intravenous argatroban injection (2.5 mg/hr) was continued in 48 hours. Regional CBF (rCBF) was measured before and after injection of argatroban using Xe-CT method. Argatroban increased CBF not only in the injured side hemisphere or penumbra, but also contralateral side of lesion in the patients with acute cerebral infarction.